OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
Jimmy Gonzalez, Benjamin Bates, Soko Setoguchi, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 24
Jimmy Gonzalez, Benjamin Bates, Soko Setoguchi, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 24
Showing 24 citing articles:
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities
Simona Sacco, Matteo Foschi, Raffaele Ornello, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1192-1205
Open Access | Times Cited: 8
Simona Sacco, Matteo Foschi, Raffaele Ornello, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1192-1205
Open Access | Times Cited: 8
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 8, pp. 696-708
Closed Access | Times Cited: 6
Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 8, pp. 696-708
Closed Access | Times Cited: 6
Salvianolic acid B ameliorates myocardial fibrosis in diabetic cardiomyopathy by deubiquitinating Smad7
Hong Luo, Lingyun Fu, Xueting Wang, et al.
Chinese Medicine (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 12
Hong Luo, Lingyun Fu, Xueting Wang, et al.
Chinese Medicine (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 12
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André Scheen
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101474-101474
Closed Access | Times Cited: 11
André Scheen
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101474-101474
Closed Access | Times Cited: 11
Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
Jincheng Shen, Amara Sarwal, Ravinder Singh, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Jincheng Shen, Amara Sarwal, Ravinder Singh, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Comparative cardiovascular effectiveness of newer glucose-lowering drugs in elderly with type 2 diabetes: a target trial emulation cohort study
Vanja Kosjerina, Mojtaba Parsa, Stine H. Scheuer, et al.
EClinicalMedicine (2025) Vol. 82, pp. 103162-103162
Closed Access
Vanja Kosjerina, Mojtaba Parsa, Stine H. Scheuer, et al.
EClinicalMedicine (2025) Vol. 82, pp. 103162-103162
Closed Access
Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta‐analysis
Zijing Zhou, Min Zheng, Zhihong Zuo, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 3, pp. 1647-1656
Open Access | Times Cited: 3
Zijing Zhou, Min Zheng, Zhihong Zuo, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 3, pp. 1647-1656
Open Access | Times Cited: 3
SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation
Yi‐Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 3
Yi‐Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 3
Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes
Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, et al.
The American Journal of Cardiology (2024) Vol. 221, pp. 52-63
Closed Access | Times Cited: 3
Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, et al.
The American Journal of Cardiology (2024) Vol. 221, pp. 52-63
Closed Access | Times Cited: 3
Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013–2021
Jimmy Gonzalez, Chintan Dave
BMC Cardiovascular Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Jimmy Gonzalez, Chintan Dave
BMC Cardiovascular Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Deciphering mortality risk of diabetes medications in heart failure patients with diabetes mellitus under triple guideline-directed medical therapy
Tuğçe Çöllüoğlu, Ahmet Çelik, Naim Ata, et al.
International Journal of Cardiology (2024) Vol. 407, pp. 132109-132109
Closed Access | Times Cited: 2
Tuğçe Çöllüoğlu, Ahmet Çelik, Naim Ata, et al.
International Journal of Cardiology (2024) Vol. 407, pp. 132109-132109
Closed Access | Times Cited: 2
Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes
Melissa R. Riester, Andrew R. Zullo, Richa Joshi, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3403-3417
Closed Access | Times Cited: 2
Melissa R. Riester, Andrew R. Zullo, Richa Joshi, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3403-3417
Closed Access | Times Cited: 2
Comparative effects of canagliflozin and sitagliptin in chronically ischemic myocardium
Sharif A. Sabe, Dwight D. Harris, Mark Broadwin, et al.
Vessel Plus (2024)
Open Access | Times Cited: 1
Sharif A. Sabe, Dwight D. Harris, Mark Broadwin, et al.
Vessel Plus (2024)
Open Access | Times Cited: 1
Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
Inês Vieira, Tânia Carvalho, Joana Saraiva, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1102-1102
Open Access | Times Cited: 1
Inês Vieira, Tânia Carvalho, Joana Saraiva, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1102-1102
Open Access | Times Cited: 1
Timing of sodium–glucose cotransporter 2 inhibitor initiation and post‐discharge outcomes in acute heart failure with diabetes: A population‐based cohort study
Che‐Yuan Wu, Baiju R. Shah, Abhinav Sharma, et al.
European Journal of Heart Failure (2024)
Open Access | Times Cited: 1
Che‐Yuan Wu, Baiju R. Shah, Abhinav Sharma, et al.
European Journal of Heart Failure (2024)
Open Access | Times Cited: 1
Semaglutide in Heart Failure With Preserved Ejection Fraction: Exploring Recent Evidence in Therapeutic Potential for the Obese Population
Josef Kusayev, Yisrael Levy, David Weininger, et al.
Cardiology in Review (2024)
Closed Access
Josef Kusayev, Yisrael Levy, David Weininger, et al.
Cardiology in Review (2024)
Closed Access
Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis
Ruirui Song, Fang Liu, Xiaojing Shi, et al.
Postgraduate Medical Journal (2024)
Closed Access
Ruirui Song, Fang Liu, Xiaojing Shi, et al.
Postgraduate Medical Journal (2024)
Closed Access
Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019
Eric Wang, Elisabetta Patorno, Farzin Khosrow‐Khavar, et al.
Diabetologia (2024)
Open Access
Eric Wang, Elisabetta Patorno, Farzin Khosrow‐Khavar, et al.
Diabetologia (2024)
Open Access
Real-Life Individual Comparison of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure and Diabetes Mellitus
Mehmet Birhan Yılmaz, Ahmet Çelik, Tuğçe Çöllüoğlu, et al.
American Journal of Cardiovascular Drugs (2024)
Closed Access
Mehmet Birhan Yılmaz, Ahmet Çelik, Tuğçe Çöllüoğlu, et al.
American Journal of Cardiovascular Drugs (2024)
Closed Access
Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100179-100179
Open Access | Times Cited: 1
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100179-100179
Open Access | Times Cited: 1
Role of Liraglutide Use in Patients With Heart Failure
Sanjana Allam, Sahil Sartaj, Hiba Moquim, et al.
Cureus (2023)
Open Access | Times Cited: 1
Sanjana Allam, Sahil Sartaj, Hiba Moquim, et al.
Cureus (2023)
Open Access | Times Cited: 1
New-onset infective endocarditis in diabetic patients receiving SGLT2I, DPP4I and GLP1a: A population-based cohort study
Oscar Hou In Chou, Tianyu Gao, Cheuk To Chung, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Oscar Hou In Chou, Tianyu Gao, Cheuk To Chung, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Salvianolic Acid B (Sal B) ameliorates myocardial fibrosis in diabetic cardiomyopathy through deubiquitinating Smad7
Hong Luo, Lingyun Fu, Xueting Wang, et al.
Research Square (Research Square) (2023)
Open Access
Hong Luo, Lingyun Fu, Xueting Wang, et al.
Research Square (Research Square) (2023)
Open Access
Implicações clínicas do uso de Inibidores de SGLT2 no manejo da insuficiência cardíaca
Renan de Almeida Benedito, Thiago Rocha Pereira de Moraes, Mariana Carvalho Murari, et al.
Revista Eletrônica Acervo Saúde (2023) Vol. 23, Iss. 12, pp. e14798-e14798
Open Access
Renan de Almeida Benedito, Thiago Rocha Pereira de Moraes, Mariana Carvalho Murari, et al.
Revista Eletrônica Acervo Saúde (2023) Vol. 23, Iss. 12, pp. e14798-e14798
Open Access
